2017 Press Releases
Altimmune to Provide Corporate Update at the BIO International Convention
June 19, 2017 - Comprehensive, Updated Corporate Presentation Now Available
GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in San Diego, California.
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
May 16, 2017 - GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer. Dr. Tasker joined the company in April 2016 as Senior Vice President, Clinical Research and Development, with responsibility for overseeing Altimmune’s clinical research and development programs.
Bill Enright, President and Chief Executive Officer of Altimmun...
Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell
May 10, 2017 - ADVISORY, May 10, 2017 (GLOBE NEWSWIRE) -- What:
Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen:
Friday, May 12, 2017 – 9:15 a.m. to 9:30 a.m. ET Altimmune Contact:
Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
May 04, 2017 - GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage dr...
PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
April 26, 2017 - ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene's stockholders at a special meeting of PharmAthene's sto...
Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
March 28, 2017 - ...
Altimmune to Present at The Bio Ceo & Investor Conference
February 06, 2017 - ...
Pharmathene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
January 19, 2017 - ...